Mineralys completes enrollment in Explore-CKD Phase 2 trial of lorundrostat; topline data expected Q2 2025

Mineralys Therapeutics, Inc.

Phase 2 trial evaluating lorundrostat for hypertension in Stage 2-3b CKD with albuminuria on stable ACEi/ARB and SGLT2i.
Primary endpoint: change from baseline in systolic BP at week 4 vs placebo; exploratory endpoint includes UACR change.
Third trial to recently complete enrollment, alongside Target-HTN, Advance-HTN, and Explore-OSA.
Topline data anticipated in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.